FDA Approves Neurotech’s ENCELTO for Treatment of Macular Telangiectasia Type 2
ENCELTO becomes the first and only FDA-approved therapy for macular telangiectasia type 2. Neurotech Pharmaceuticals (Rhode Island, United States) announced…
Glimmers of Hope: Next-Gen Pediatric Retina Care Promises to Deliver Solutions Once Deemed Out of Reach
Relentless innovation, global collaboration and dedicated specialists are driving a promising future for pediatric retina care, bringing solutions once thought…
popular posts
latest posts
